share_log

Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide

Recor Medical Champions Global Action on World Hypertension Day: Early Intervention and Continued Innovation Crucial in Tackling This Silent Killer Impacting Billions Worldwide

Recor Medical Champions 世界高血壓日的全球行動:早期干預和持續創新對於應對這種影響全球數十億人的無聲殺手至關重要
PR Newswire ·  05/17 03:00

FRANKFURT, GERMANY and PALO ALTO, Calif., May 17, 2024 /PRNewswire/ -- Hypertension, or high blood pressure, affects one in three Europeans over the age of 30 and more than one billion people worldwide. Hypertension is known as the "silent killer" because many people do not know they have it and, over time, it can lead to serious health issues. Hypertension is the number one contributor to the burden of human disease globally, has been associated with a five-year reduction in life expectancy and is a major risk factor for heart disease, stroke, heart attacks and other serious health problems.

德國法蘭克福和加利福尼亞州帕洛阿爾託,2024年5月17日 /PRNewswire/ — 高血壓影響着三分之一的30歲以上的歐洲人和全球超過十億人。高血壓被稱爲 “沉默的殺手”,因爲許多人不知道自己患有高血壓,隨着時間的推移,它可能導致嚴重的健康問題。高血壓是全球人類疾病負擔的第一大因素,與預期壽命縮短五年有關,是心臟病、中風、心臟病發作和其他嚴重健康問題的主要危險因素。

Bloodpressure Measurement is important with Hypertension
血壓測量對高血壓很重要

May 17 is World Hypertension Day, a global initiative to highlight the importance of monitoring blood pressure and provide education about this devastating chronic disease. Recor Medical – the pioneer of the Paradise Ultrasound Renal Denervation (uRDN) System, a recently FDA-approved medical device-based procedure to treat hypertension – is joining the fight by promoting awareness and encouraging continued innovation and equitable access to early intervention and sustainable solutions for patients suffering from this chronic disease.

5月17日是世界高血壓日,這是一項全球倡議,旨在強調監測血壓的重要性並提供有關這種毀滅性慢性病的教育。Recor Medical是天堂超聲腎去神經分化(uRdN)系統的先驅,該系統是美國食品藥品管理局最近批准的一種基於醫療器械的高血壓治療程序。Recor Medical正在加入這場鬥爭,提高認識,鼓勵持續創新,讓患有這種慢性病的患者公平獲得早期干預和可持續的解決方案。

According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment. Furthermore, left undetected or uncontrolled, hypertension is a leading contributor to other long-term risks, including:

根據世界衛生組織的一份報告,在1990年至2019年之間,患有高血壓的成年人人數翻了一番,從6.5億增加到13億。該報告還指出,只有54%的成年高血壓患者被診斷出來,只有42%的人接受了治療。此外,如果不被發現或不受控制,高血壓是導致其他長期風險的主要因素,包括:

  • Chronic kidney disease or failure
  • Vision loss
  • Sexual dysfunction
  • Dementia
  • Uterine fibroids.
  • 慢性腎臟疾病或衰竭
  • 視力喪失
  • 性功能障礙
  • 癡呆
  • 子宮肌瘤。

About one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, innovation and investment in new solutions are vital to achieve blood pressure control and realize a healthier future. From pharmaceutical treatments to technology, patients need new therapies that can provide life-changing results. This includes medical device-based therapies, like the Paradise Ultrasound Renal Denervation (uRDN) system, an additional treatment option for patients who remain uncontrolled and at elevated cardiovascular risk despite standard lifestyle changes and treatment with oral medications.

儘管改變了健康的生活方式並服用了三種以上的藥物,但在接受高血壓治療的患者中,約有三分之一的患者仍然無法控制。對於這些患者而言,創新和對新解決方案的投資對於實現血壓控制和實現更健康的未來至關重要。從藥物治療到技術,患者需要能夠提供改變生活效果的新療法。這包括基於醫療設備的療法,例如天堂超聲腎臟去神經分化(uRdN)系統,這是一種額外的治療選擇,適用於儘管生活方式改變和口服藥物治療但仍無法控制且心血管風險較高的患者。

"While new technologies like Recor's Paradise uRDN system are helping patients in the fight against hypertension and making a significant impact on people's lives, we know education, early intervention and hypertension management are critical first steps to treating this chronic disease," said Lara Barghout, President and CEO of Recor Medical. "We support the efforts of World Hypertension Day and will continue to advocate with providers and for patients to mitigate the effects of this disease before it progresses."

Recor Medical總裁兼首席執行官拉拉·巴爾豪特表示:“儘管像Recor的Paradise uRDN系統這樣的新技術正在幫助患者對抗高血壓並對人們的生活產生重大影響,但我們知道教育、早期干預和高血壓管理是治療這種慢性病的關鍵第一步。”“我們支持世界高血壓日的努力,並將繼續向提供者和患者倡導在該疾病進展之前減輕其影響。”

"Physicians and their patients who struggle with hypertension are in need of innovative solutions. And, for those with uncontrolled resistant hypertension, technology is becoming an increasingly important option to help control this disease. All interventions need to be considered to tackle this global problem," Barghout added.

“患有高血壓的醫生及其患者需要創新的解決方案。而且,對於那些無法控制的耐藥性高血壓患者來說,技術正成爲幫助控制這種疾病的越來越重要的選擇。需要考慮所有干預措施來解決這個全球性問題,” 巴爾豪特補充說。

Recor Medical's Paradise uRDN system is a first-of-its-kind ultrasound-based renal denervation (RDN) technology designed to lower blood pressure by denervating overactive sympathetic nerves surrounding the renal arteries. Paradise uRDN delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through each of the main renal arteries to the surrounding nerves. The Paradise catheter features the exclusive HydroCooling system, which circulates sterile water through the balloon during the procedure to help cool and protect the inner layers of the renal artery.

Recor Medical 的 Paradise uRDN 系統是首款基於超聲波的腎臟去神經分配 (RDN) 技術,旨在通過削弱腎動脈周圍過度活躍的交感神經來降低血壓。Paradise UrDN 通過每條主要腎動脈向周圍神經輸送兩到三劑量 360 度超聲波能量,每次持續七秒鐘。天堂導管採用獨有的 HydroCooling 系統,該系統可在手術過程中通過氣球循環無菌水,幫助冷卻和保護腎動脈內層。

About Recor Medical, Inc.

關於 Recor Medical, Inc.

Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise system in patients with mild-to-moderate and resistant hypertension. In addition, Recor has begun the Global Paradise System ("GPS") Registry in the European Union and the UK, with plans to expand globally.

Recor Medical總部位於加利福尼亞州帕洛阿爾託,是大冢醫療器械有限公司的全資子公司,是一家專注於高血壓管理轉型的醫療技術公司。Recor率先使用天堂超聲腎去神經系統治療高血壓。Paradise系統是日本的研究設備,已獲得美國食品藥品管理局的批准,並帶有CE標誌。Recor報告了三項針對輕度至中度耐藥性高血壓患者的天堂系統的獨立、隨機、虛假對照的研究取得了積極的結果。此外,Recor已開始在歐盟和英國設立全球天堂系統(“GPS”)登記處,並計劃向全球擴張。

About Otsuka Medical Devices

關於大冢醫療器械

Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).

Otsuka Medical Devices Co., Ltd. 從事醫療器械的全球開發和商業化,這些設備爲無法通過藥物或其他常規治療滿足患者需求的領域提供新的治療選擇。大冢醫療器械是大冢控股有限公司 () 的子公司,該公司是一家在東京證券交易所上市的全球醫療保健公司(JP 4578)。

The original press release can be seen at

原始新聞稿可以在以下網址查看

Media-Contact

媒體聯繫方式

Jennifer Disper-Wilmsen
Senior Manager Communications EMEA
Otsuka Medical Devices Europe GmbH (Recor Medical)
+49 (171) 17 68 49 0
[email protected]

詹妮弗·迪斯珀-威爾森
歐洲、中東和非洲地區傳播高級經理
大冢醫療器械歐洲有限公司(Recor Medical)
+49 (171) 17 68 49 0
[電子郵件保護]

Photo:
Logo:

照片:
徽標:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論